Amneal Pharmaceuticals reported second-quarter revenue of $796.2 million, up 9.9% year on year and beating analyst estimates by 3.6%, while adjusted earnings per share of $0.30 exceeded consensus by 30.3%. The company raised its full-year revenue guidance to $3.15 billion at the midpoint, a 1.6% increase from the prior outlook, and slightly lifted its adjusted EPS guidance to $1.01. Management attributed the strong performance to robust demand for transdermal patches in women's health, uptake of new complex generics, and growth in branded neurology products such as CREXONT and BREKIYA. The pending acquisition of Kashiv Biosciences is expected to establish Amneal as a fully integrated biosimilars player, with plans to launch six commercial biosimilars by next year targeting a market exceeding $14 billion. The company also highlighted upcoming launches of high-value generics like lanreotide and capacity expansion to meet surging demand.
Amneal Pharmaceuticals, Inc. Class A Common StockQ2 revenue and EPS beat, raised full-year guidance
Pending acquisition by Amneal expected to establish fully integrated biosimilars player